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The successful brain graftings in hemiparkin-
sonian non-human primates using adrenal
medullary (AM)/peripheral nerve (PN) co-grafts
suggest that in humans, AM brain grafting for
the treatment of Parkinson’s disease (PD) could
be improved by co-grafting with PN. The benefi-
cial effects of AM/PN co-grafting in non-human
primates have been attributed to the
neuronotrophic support of the PN for the
improved survival and neurogenization of the
grafted AM chromaffin cells. The potential of
such support on the functional effect of AM
grafts in PD patients has recently been evaluated
using a continuous nerve growth factor intra-
putaminal infusion. Here we report our initial
experience with AM/PN co-grafting in four
patients with PD.
The four parkinsonian subjects were three
males (JTN, ORF, JRD) and one female (DBB),
41-51 years old, with an evolution of PD of 5-13
years, characterized by bradykinesia (BK) and
rigidity (R) (JTN, DBB, ORF), and by tremor
(T) and rigidity (R) (JRD). All patients had
been on levodopa (560-1000 rag) for 4-8 years,
and continue to respond well to the medication.
Their presurgery scores on the Unified Parkin-
sonism Rating Scale (UPRS), the Hoehn &
Yahr (H&Y), Schwab & England (S&E), and
Madrazo (M) scales were, in "ON"/"OFF": JTN,
78/97, /4, 70%/50%, and 3/2; DBB, 35/73, 2.5/4,
90%/60%, and 4/2; ORF, 47/87, 2.5/4, 80%/50%,
and 4/2; and JRD, 33/79, 2.5/4, 80%/.60%, and
4/2. Using open microsurgery, autologous AM
fragments were implanted to the right caudate
nucleus together with freshly dissected, minced
intercostal nerve tissue. Eighteen to 31 months
after surgery, DBB and ORF have reduced their
levodopa doses (in rag/day) from 750 to 500 and
660, respectively, with mild (DBB) or moderate
(ORF) dyskinesia as a side effect. JTN has
increased his dosage from 560 to 660 rag/day.
The patients’ postsurgery PD scores (UPRS,
H&Y, S&E, and M) were: JTN, 27/54, 2/2.5,
90%/80%, and 4.5/4; DBB, 25/61, 2.5/4,
90%/50%, and 4/2; ORF, 53/75, 2/2.5, 70%/60%,
and 4.5/4; RJD, 29/66, 2.5/3, 100%/60%, and 4/3.
The amount of change of their total UPRS
scores in "ON" and "OFF" is shown in Fig. 1, and
compared with the mean level of change in
UPRS scoring of a heterogeneous population
(HET POP) of 18 AM-alone transplanted PD
patients. Only the functional recovery in "OFF"
of JTN was comparable to the mean level of re-
covery of the AM-alone transplanted PD pa-
tients, and in "ON" was even higher by 16 points.
The recoveries in "ON" and "OFF" of the other 3
patients were similar to each other, but much
lower than that of the 18 AM-alone grafted PD
patients; in "ON", ORF showed some deteriora-
tion. Regardless of the amount of change in their
UPRS scorings, all patients showed improve-
ment in the quality of their daily living activities.
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AM/PN postsurgery evolution. The changes in total UPRS score are depicted for each patient (JTN, BDD,
ORF, RJD) at the indicated follow-up times given in months (mo), and compared to the mean change in
total UPRS score for a heterogeneous population (HET POP) of PD patients (n=18) 12-27 mo after
autologous AM-alone brain grafting to the caudate nucleus. BK/R, bradykinesiaJrigidity; T/R,
tremor/rigidity.